Literature DB >> 8861916

The crystal structure of hepatitis C virus NS3 proteinase reveals a trypsin-like fold and a structural zinc binding site.

R A Love1, H E Parge, J A Wickersham, Z Hostomsky, N Habuka, E W Moomaw, T Adachi, Z Hostomska.   

Abstract

During replication of hepatitis C virus (HCV), the final steps of polyprotein processing are performed by a viral proteinase located in the N-terminal one-third of nonstructural protein 3. The structure of NS3 proteinase from HCV BK strain was determined by X-ray crystallography at 2.4 angstrom resolution. NS3P folds as a trypsin-like proteinase with two beta barrels and a catalytic triad of His-57, Asp-81, Ser-139. The structure has a substrate-binding site consistent with the cleavage specificity of the enzyme. Novel features include a structural zinc-binding site and a long N-terminus that interacts with neighboring molecules by binding to a hydrophobic surface patch.

Entities:  

Mesh:

Substances:

Year:  1996        PMID: 8861916     DOI: 10.1016/s0092-8674(00)81350-1

Source DB:  PubMed          Journal:  Cell        ISSN: 0092-8674            Impact factor:   41.582


  106 in total

1.  Inhibitor binding induces active site stabilization of the HCV NS3 protein serine protease domain.

Authors:  G Barbato; D O Cicero; F Cordier; F Narjes; B Gerlach; S Sambucini; S Grzesiek; V G Matassa; R De Francesco; R Bazzo
Journal:  EMBO J       Date:  2000-03-15       Impact factor: 11.598

2.  Isolation and characterization of monoclonal antibodies that inhibit hepatitis C virus NS3 protease.

Authors:  T Ueno; S Misawa; Y Ohba; M Matsumoto; M Mizunuma; N Kasai; K Tsumoto; I Kumagai; H Hayashi
Journal:  J Virol       Date:  2000-07       Impact factor: 5.103

3.  Conformational changes in the NS3 protease from hepatitis C virus strain Bk monitored by limited proteolysis and mass spectrometry.

Authors:  S Orrù; F Dal Piaz; A Casbarra; G Biasiol; R De Francesco; C Steinkühler; P Pucci
Journal:  Protein Sci       Date:  1999-07       Impact factor: 6.725

4.  Mutations that affect dimer formation and helicase activity of the hepatitis C virus helicase.

Authors:  Y L Khu; E Koh; S P Lim; Y H Tan; S Brenner; S G Lim; W J Hong; P Y Goh
Journal:  J Virol       Date:  2001-01       Impact factor: 5.103

Review 5.  Update in internal medicine.

Authors:  F López-Jiménez; M Brito; Y W Aude; P Scheinberg; M Kaplan; D A Dixon; N Schneiderman; J F Trejo; L H López-Salazar; E J Ramírez-Barba; R Kalil; C Ortiz; J Goyos; A Buenaño; S Kottiech; G A Lamas
Journal:  Arch Med Res       Date:  2000 Jul-Aug       Impact factor: 2.235

6.  Molecular biology and the diagnosis and treatment of liver diseases.

Authors:  Howard J Worman; Lin Feng; Naoto Mamiya
Journal:  World J Gastroenterol       Date:  1998-06       Impact factor: 5.742

7.  Molecular biology of liver disorders:the hepatitis C virus and molecular targets for drug development.

Authors:  Howard J Worman; Feng Lin
Journal:  World J Gastroenterol       Date:  2000-08       Impact factor: 5.742

8.  Identification of mouse hepatitis virus papain-like proteinase 2 activity.

Authors:  A Kanjanahaluethai; S C Baker
Journal:  J Virol       Date:  2000-09       Impact factor: 5.103

9.  Probing the substrate specificity of hepatitis C virus NS3 serine protease by using synthetic peptides.

Authors:  R Zhang; J Durkin; W T Windsor; C McNemar; L Ramanathan; H V Le
Journal:  J Virol       Date:  1997-08       Impact factor: 5.103

10.  A macrocyclic HCV NS3/4A protease inhibitor interacts with protease and helicase residues in the complex with its full-length target.

Authors:  Nikolaus Schiering; Allan D'Arcy; Frederic Villard; Oliver Simic; Marion Kamke; Gaby Monnet; Ulrich Hassiepen; Dmitri I Svergun; Ruth Pulfer; Jörg Eder; Prakash Raman; Ursula Bodendorf
Journal:  Proc Natl Acad Sci U S A       Date:  2011-12-12       Impact factor: 11.205

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.